Leukemia Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Leukemia Therapeutics Market Growth and it is segmented by Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, and Others), Type of Leukemia (Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The Market values are Provided (in USD million) for the above segments.

Leukemia Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Leukemia Therapeutics Market Size

Leukemia Therapeutics Market Summary
Study Period 2020 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 5.50 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Leukemia Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Leukemia Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Leukemia Therapeutics Market Analysis

The Global Leukemia Therapeutics Market is expected to register a CAGR of 5.5% during the forecast period.

Because most elective treatments were postponed due to the COVID-19 pandemic, treatment of hematologic malignancies was also impacted significantly.However, delayed treatment is not recommended for severe diseases, especially acute leukemia, and thus, necessary guidelines and measures were put forth recently to allow leukemia treatments during the pandemic with all protective measures. As per the study published in December 2021 by the National Library of Medicine, there were 4.1 million cancer-related encounters, 3.9 million relevant procedures, and 251,647 new cancer cases diagnosed. Compared to the annual averages in 2018 through 2019, colonoscopies in 2020 decreased by 45%, whereas prostate biopsies, chest computed tomography scans, and cystoscopies decreased by 29%, 10%, and 21%, respectively. New cancer diagnoses decreased by 13% to 23%. However, the market growth is stabilizing in the current scenario after COVID-19 as the worldwide restrictions have eased and disease screening services have been resumed.

The leukemia therapeutics market is mainly driven by a rise in the prevalence of leukemia, a surge in awareness related to early detection and treatment of leukemia, and rising investment in the healthcare sector. A significant number of the population across the globe suffers from leukemia. For instance, as per the statistics by GLOBOCAN 2020, leukemia accounted for 475,000 cases for both sexes of all ages in 2020; these cases are expected to increase and reach up to 692,000 by 2040, worldwide. In addition, as per the 2021 statistics from the Leukemia & Lymphoma Society, an estimated 397,501 people were living with or in remission from leukemia in the United States. Hence, the overall statistics show that there is a huge number of people that suffer from leukemia, which is expected to boost the growth of the market in the forecast period.

Furthermore, the increasing number of investments being made in research and development has enabled several pharmaceutical and biotechnology companies to focus on and develop novel and effective drugs. For instance, in April 2021, the Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP) reported five new investments aimed at speeding up the development of new and improved immunotherapies for the treatment of blood cancers in the United States. Over the past few decades, the LLS has spent more than $100 million on grants and TAP investments to move forward innovative ways to use cellular immunotherapies to fight blood cancers.

Additionally, in May 2022, Servier received US FDA approval for TIBSOVO (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years of age or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. Moreover, in March 2022, Sumitomo Dainippon Pharma Oncology, Inc. will dose patients in a Phase I/II study of DSP-5336, an inhibitor of melanin binding to mixed-lineage leukemia (MLL) proteins, in patients with relapsed or refractory acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). Thus, increasing clinical trials by the key players is expected to boost the growth of the market over the forecast period.

As a result of the aforementioned factors, the market is expected to grow. However, the high treatment costs and stringent regulatory environment restrained market growth over the forecast period.

Leukemia Therapeutics Industry Overview

The Leukemia Therapeutics Market is competitive. Product approvals are a key strategy adopted by key players to enhance their dominance in this market. Some of the major players in the market are Amgen Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Incyte Corp., Johnson & Johnson, Novartis, Pfizer Inc., and Sanofi, which are providing these products across the globe.

Leukemia Therapeutics Market Leaders

  1. Amgen Inc.

  2. Bristol-Myers Squibb Company

  3. F. Hoffmann-La Roche Ltd

  4. Novartis International AG

  5. Sanofi S.A.

  6. *Disclaimer: Major Players sorted in no particular order
Leukemia Therapeutics Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Leukemia Therapeutics Market News

  • November 2022: BeiGene announced that the European Council approved Brukinsa (zanubrutinib) for the treatment of adult patients with treatment-naive (TN) or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).
  • October 2022: The US FDA approved quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD-positive AML.

Leukemia Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Leukemia
    • 4.2.2 Surge in Awareness Related to Early Detection and Treatment of Leukemia
    • 4.2.3 Rising Investment in Healthcare Sector
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Stringent Regulatory Scenario for Product Approval
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Treatment Type
    • 5.1.1 Chemotherapy
    • 5.1.2 Immunotherapy
    • 5.1.3 Targeted Therapy
    • 5.1.4 Other Treatment Types
  • 5.2 By Type of Leukemia
    • 5.2.1 Acute Lymphocytic Leukemia
    • 5.2.2 Acute Myeloid Leukemia
    • 5.2.3 Chronic Lymphocytic Leukemia
    • 5.2.4 Chronic Myeloid Leukemia
    • 5.2.5 Other Types of Leukemia
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 AstraZeneca plc
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 F. Hoffmann-La Roche Ltd.
    • 6.1.5 Incyte Corp
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Novartis International AG
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Sanofi S.A.
    • 6.1.10 Teva Pharmaceutical
    • 6.1.11 Astellas Pharma
    • 6.1.12 Otsuka Holdings Co., Ltd.
    • 6.1.13 BeiGene
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Leukemia Therapeutics Industry Segmentation

As per the scope of the report, leukemia is a burgeoning blood cancer that forms in the bone marrow and eventually leads to the uncontrolled growth of blood cells. Among other cancer types, leukemia is emerging as a life-impinging threat globally. The leukemia therapeutic market consists of different therapeutics advised by the physician for the treatment of leukemia. The market is segmented by Treatment Type (chemotherapy, immunotherapy, targeted therapy, and others), Type of Leukemia (acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and others), and Geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Type Chemotherapy
Immunotherapy
Targeted Therapy
Other Treatment Types
By Type of Leukemia Acute Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Other Types of Leukemia
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Leukemia Therapeutics Market Research FAQs

What is the current Global Leukemia Therapeutics Market size?

The Global Leukemia Therapeutics Market is projected to register a CAGR of 5.5% during the forecast period (2025-2030)

Who are the key players in Global Leukemia Therapeutics Market?

Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Novartis International AG and Sanofi S.A. are the major companies operating in the Global Leukemia Therapeutics Market.

Which is the fastest growing region in Global Leukemia Therapeutics Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Leukemia Therapeutics Market?

In 2025, the North America accounts for the largest market share in Global Leukemia Therapeutics Market.

What years does this Global Leukemia Therapeutics Market cover?

The report covers the Global Leukemia Therapeutics Market historical market size for years: 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Leukemia Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Leukemia Therapeutics Industry Report

Statistics for the 2025 Global Leukemia Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Leukemia Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.